| Literature DB >> 30116317 |
Ying He1,2, Wen Yao3, Meng Zhang1, Ying Zhang1, Dan Zhang1, Zhuocheng Jiang1, Tianyou Ma1, Jian Sun4, Mingming Shao1, Jinghong Chen1.
Abstract
The molecular mechanisms underlying osteoarthritis (OA) and Kashin-Beck disease (KBD) remain poorly understood. Hypertrophic chondrocytes serve an important role in the development of both OA and KBD, whereas oxidative stress can contribute to the pathological progression of cartilage damage. Therefore, the aim of the present study was to detect altered expression of osteogenesis-related genes in hypertrophic chondrocytes, following treatment with 3-morpholinosydnonimine (SIN-1). ATDC5 cells were induced to develop into hypertrophic chondrocytes via Insulin-Transferrin-Selenium. The appropriate concentration and time of SIN-1 treatment was determined via MTT assay. Following hypertrophic chondrocyte stimulation with SIN-1, a liquid chip was analyzed using a polymerase chain reaction (PCR) array. Reverse transcription-quantitative PCR was conducted on individual genes to validate the array-based data. Analyses of protein-protein interactions, gene ontology functions and Kyoto Encyclopedia of Genes and Genomes pathway enrichment of the differentially expressed genes were also performed. A total of 6 upregulated and 34 downregulated genes were identified, including the mothers against decapentaplegic homolog (Smad) family (Smad1-4), bone morphogenetic proteins and their receptors (Bmp2, Bmp3, Bmpr1α and Bmpr1β), and matrix metalloproteinases (MMP2,-9 and-10). These genes are associated with collagen biology, transcriptional control, skeletal development, bone mineral metabolism, and cell adhesion. SIN-1 induced death of hypertrophic chondrocytes likely through TGF-β/Smad or BMP/Smad pathways. Oxidative-stress-dependent induction of abnormal gene expression may be associated with chondronecrosis in the cartilage of patients with OA or KBD.Entities:
Keywords: 3-morpholinosydnonimine; Kashin-Beck disease; gene expression; hypertrophic chondrocytes; osteoarthritis
Year: 2018 PMID: 30116317 PMCID: PMC6090273 DOI: 10.3892/etm.2018.6261
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Primers used in reverse transcription-quantitative polymerase chain reaction experiments.
| Genes | Forward primer (5′-3′) | Reverse primer (5′-3′) |
|---|---|---|
| GAPDH | GGGCTCATGACCACAGTCCATGC | CCTTGCCCACAGCCTTGGCA |
| Col X | ACGCATCTCCCAGCACCAGAATC | GGGGCTAGCAAGTGGGCCCT |
| Runx2 | GGTTGTAGCCCTCGGAGAGG | GCCATGACGGTAACCACAGTC |
| Smad1 | AAAGACCTGTGGCTTCCGTCT | TTATCGTGGCTCCTTCGTCAG |
| Smad2 | ATGTCGTCCATCTTGCCATTC | AACCGTCCTGTTTTCTTTAGCTT |
| Smad3 | GCTGCCCTCCTAGCTCAG | GGTGCTGGTCACTGTCTGTC |
| Smad4 | GAGAACATTGGATGGACGACT | CACAGACGGGCATAGATCAC |
| Col2a1 | CCAGCTGACCTCGCCACTGC | GGGTCCAGGCGCACCCTTTT |
| MMP10 | GCAGCCCATGAACTTGGCCACT | AGGGACCGGCTCCATACAGGG |
| Vcam1 | GATAGACAGCCCACTAAACGCG | GAATCTCTGGATCCTTGGGG |
Col X, type X collagen; Runx2, runt-related transcription factor 2; Smad, mothers against decapentaplegic homolog; Col 2a, collagen, type II, α; MMP10, matrix metalloproteinase 10; Vcam1, vascular cell adhesion molecule 1.
Figure 1.Establishment of the hypertrophic chondrocyte model. The mRNA expression levels of (A) Col X and (B) Runx2 during the differentiation process were detected by reverse transcription-quantitative polymerase chain reaction. The group treated for 7 days served as a control. Simultaneously, protein expression levels of (C) Col X and (D) Runx2 were assessed via western blotting. Data are expressed as the mean ± standard deviation from three independent experiments. *P<0.05 vs. day 7. Col X, type X collagen; Runx2, runt-related transcription factor 2.
Figure 2.Viability of hypertrophic chondrocytes treated with SIN-1. (A) Cells were treated with 0, 1, 5 or 10 mM SIN-1 for 4 h. (B) Cells were treated with 0, 1, 2, 3, 4 or 5 mM SIN-1 for 24 h. Data are expressed as the mean ± standard deviation from three independent experiments. *P<0.05 vs. 0 mM. SIN-1, 3-morpholinosydnonimine.
Figure 3.A scatter plot of 84 genes associated with osteoarthritis. Genes whose expression levels were altered by ≥3-fold were deemed differentially expressed. Upregulated genes are marked with a red circle, whereas downregulated genes are marked with a green circle. Black circles represent genes whose expression was unchanged. SIN-1, 3-morpholinosydnonimine.
Significantly downregulated genes in hypertrophic chondrocytes treated with 3-morpholinosydnonimine.
| No. | ID | Symbol | Description | Fold regulation |
|---|---|---|---|---|
| 1 | NM_013465 | Ahsg | α-2-HS-glycoprotein | −6.19 |
| 2 | NM_007553 | BMP2 | Bone morphogenetic protein 2 | −6.11 |
| 3 | NM_173404 | BMP3 | Bone morphogenetic protein 3 | −8.52 |
| 4 | NM_009758 | BMPR1a | Bone morphogenetic protein receptor, type 1A | −4.17 |
| 5 | NM_007560 | BMPR1b | Bone morphogenetic protein receptor, type 1B | −7.16 |
| 6 | NM_007643 | Cd36 | Cluster of differentiation 36 antigen | −7.26 |
| 7 | NM_009866 | Cdh11 | Cadherin 11 | −3.05 |
| 8 | NM_009893 | Chrd | Chordin | −5.28 |
| 9 | NM_009925 | Col10a1 | Collagen, type X, α 1 | −4.03 |
| 10 | NM_016685 | Comp | Cartilage oligomeric matrix protein | −5.17 |
| 11 | NM_007802 | Ctsk | Cathepsin K | −3.14 |
| 12 | NM_010197 | Fgf1 | Fibroblast growth factor 1 | −7.89 |
| 13 | NM_010206 | Fgfr1 | Fibroblast growth factor receptor 1 | −11.16 |
| 14 | NM_010207 | Fgfr2 | Fibroblast growth factor receptor 2 | −3.34 |
| 15 | NM_010228 | Flt1 | FMS-like tyrosine kinase 1 | −7.41 |
| 16 | NM_010512 | Igf1 | Insulin-like growth factor 1 | −3.48 |
| 17 | NM_008396 | Itga2 | Integrin α 2 | −4.76 |
| 18 | NM_008402 | Itgav | Integrin α V | −7.52 |
| 19 | NM_010578 | Itgb1 | Integrin β 1 (fibronectin receptor β) | −4.20 |
| 20 | NM_019471 | MMP10 | Matrix metalloproteinase 10 | −45.25 |
| 21 | NM_008610 | MMP2 | Matrix metalloproteinase 2 | −3.66 |
| 22 | NM_013599 | MMP9 | Matrix metalloproteinase 9 | −4.66 |
| 23 | NM_008689 | Nfkb1 | Nuclear factor of κ light polypeptide gene enhancer in B cells 1, p105 | −3.66 |
| 24 | NM_011077 | Phex | Phosphate regulating gene with homologies to endopeptidases on the X chromosome | −4.44 |
| 25 | NM_008539 | Smad1 | Mothers against decapentaplegic homolog 1 (Drosophila) | −3.89 |
| 26 | NM_010754 | Smad2 | Mothers against decapentaplegic homolog 2 (Drosophila) | −3.10 |
| 27 | NM_016769 | Smad3 | Mothers against decapentaplegic homolog 3 (Drosophila) | −4.63 |
| 28 | NM_008540 | Smad4 | Mothers against decapentaplegic homolog 4 (Drosophila) | −4.17 |
| 29 | NM_009367 | Tgfb2 | Transforming growth factor, β 2 | −5.31 |
| 30 | NM_009370 | Tgfbr1 | Transforming growth factor, β receptor I | −16.00 |
| 31 | NM_009371 | Tgfbr2 | Transforming growth factor, β receptor II | −5.70 |
| 32 | NM_013693 | Tnf | Tumor necrosis factor | −9.19 |
| 33 | NM_011613 | Tnfsf11 | Tumor necrosis factor (ligand) superfamily, member 11 | −4.14 |
| 34 | NM_011693 | Vcam1 | Vascular cell adhesion molecule 1 | −6.68 |
Differentially expressed genes that were deemed differentially expressed by 3-fold or greater are presented.
Significantly upregulated genes in hypertrophic chondrocytes treated with 3-morpholinosydnonimine.
| No. | ID | Symbol | Description | Fold regulation |
|---|---|---|---|---|
| 1 | NM_007542 | Bgn | Biglycan | 5.82 |
| 2 | NM_007555 | Bmp5 | Bone morphogenetic protein 5 | 7.26 |
| 3 | NM_007743 | Col1a2 | Collagen, type I, α 2 | 4.08 |
| 4 | NM_031163 | Col2a1 | Collagen, type II, α 1 | 7.26 |
| 5 | NM_010544 | Ihh | Indian hedgehog | 3.32 |
| 6 | NM_024449 | Sost | Sclerostin | 4.26 |
Differentially expressed genes that were deemed differentially expressed by 3-fold or greater are presented.
Figure 4.A histogram presenting mRNA expression levels of 8 selected genes in hypertrophic chondrocytes treated with 3-morpholinosydnonimine. GAPDH served as an internal control. Data are expressed as the mean ± standard deviation. PCR, polymerase chain reaction; RT-qPCR, reverse transcription-quantitative PCR; Smad, mothers against decapentaplegic homolog; Col X, type X collagen; MMP, matrix metalloproteinase; Vcam1, vascular cell adhesion molecule 1; Col 2a, collagen, type II, α.
Figure 5.Network of protein-protein interactions for differentially expressed genes.
Results on top five GO functions and KEGG pathway enrichment analysis of differentially expressed genes.
| Function and pathway | ID | Description | Count in gene set | False discovery rate |
|---|---|---|---|---|
| Biological process | GO: 0001501 | Skeletal system development | 20 | 2.03×10−20 |
| (GO) | GO: 0009888 | Tissue development | 27 | 3.18×10−19 |
| GO: 0001503 | Ossification | 16 | 2.27×10−18 | |
| GO: 0071495 | Cellular response to endogenous stimulus | 21 | 4.40×10−18 | |
| GO: 0071363 | Cellular response to growth factor stimulus | 17 | 5.39×10−18 | |
| Molecular function | GO: 0046332 | Mothers against decapentaplegic homolog binding | 10 | 5.84×10−14 |
| (GO) | GO: 0005515 | Protein binding | 32 | 4.67×10−13 |
| GO: 0005160 | Transforming growth factor β receptor binding | 8 | 1.02×10−11 | |
| GO: 0005126 | Cytokine receptor binding | 10 | 1.09×10−9 | |
| GO: 0019838 | Growth factor binding | 8 | 1.58×10−9 | |
| Cellular component | GO: 0005615 | Extracellular space | 20 | 2.99×10−13 |
| (GO) | GO: 0044421 | Extracellular region part | 26 | 2.01×10−10 |
| GO: 0005576 | Extracellular region | 27 | 3.32×10−10 | |
| GO: 0031012 | Extracellular matrix | 12 | 3.32×10−10 | |
| GO: 0005578 | Proteinaceous extracellular matrix | 11 | 1.35×10−9 | |
| KEGG pathways | 4350 | Transforming growth factor-β signaling pathway | 13 | 1.50×10−20 |
| 5200 | Pathways in cancer | 17 | 2.04×10−19 | |
| 4390 | Hippo signaling pathway | 12 | 1.87×10−15 | |
| 5205 | Proteoglycans in cancer | 12 | 1.53×10−13 | |
| 4151 | Phosphoinositide 3-kinase-protein kinase B signaling pathway | 12 | 2.49×10−11 |
GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.
Figure 6.Analysis of signaling pathways for differentially expressed genes.